- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06388889
Phase III Long-Term Extension Study With Dexpramipexole (EXHALE-5)
April 24, 2024 updated by: Areteia Therapeutics
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants With Severe Eosinophilic Asthma
The goal of this clinical trial] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥12 years, on Global Initiative for Asthma (GINA) 2021 [GINA, 2021] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
1600
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33607
- Research Site 20001-004
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants who completed the double-blind study intervention treatment period during either of the Phase III studies EXHALE-2 or EXHALE-3.
- Participants capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Baseline Visit/Day 1.
WOCBP (after menarche) must use either of the following methods of birth control, from the Baseline Visit/Day 1 through the End of Study Visit:
- A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system, levonorgestrel intrauterine system, or oral contraceptive. -OR-
- Two protocol acceptable methods of contraception in tandem. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for ≥12 months prior to the planned date of the Baseline Visit/Day 1 without an alternative medical cause. The following age specific requirements apply:
- Women <50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range.
- Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
Exclusion Criteria:
- Clinically significant change in health status during either of the Phase III studies EXHALE-2 or EXHALE-3 which in the opinion of the investigator would make the participant unsuitable for participation in this study.
- Participants with allergy/intolerance to dexpramipexole or any of its excipients.
- Participants who met permanent discontinuation criteria or permanently discontinued study treatment for any reason in either of the Phase III studies EXHALE-2 or EXHALE-3..
- Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days.
- Pregnant or breastfeeding women.
- Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 150 mg BID
Dexpramipexole 150 mg oral tablet taken twice a day.
|
Oral administration of dexpramipexole tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and Percentage of Participants with a Treatment Emergent Adverse Event
Time Frame: 52 weeks
|
Summary of participants from the safety population who experienced an adverse event.
|
52 weeks
|
Number and Percentage of Participants with Potentially Clinically Significant Postbaseline Changes in Clinical Laboratory Evaluations
Time Frame: 52 weeks
|
Summary of participants from the safety population who experienced potentially clinically significant postbaseline changes in hematology and chemistry results.
|
52 weeks
|
Number and Percentage of Participants with Potentially Clinically Significant Postbaseline Changes in Vital Signs and Body Weight
Time Frame: 52 weeks
|
Summary of participants from the safety population who experienced potentially clinically significant postbaseline changes in vital signs (blood pressure, pulse rate, respiratory rate, and temperature) or body weight.
|
52 weeks
|
Number and Percentage of Participants with Potentially Significant Postbaseline Changes in Electrocardiogram Parameters
Time Frame: 52 weeks
|
Summary of participants from the safety population who experienced potentially significant postbaseline changes in electrocardiogram parameters: heart rate, PR, QRS and QTcF intervals.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severe Asthma Exacerbations
Time Frame: Averaged across 52 weeks
|
Annualized rate of severe asthma exacerbations over 52 weeks
|
Averaged across 52 weeks
|
Change in Asthma Control Questionnaire-6 (ACQ-6)
Time Frame: Day 1 (baseline), Weeks 16, 32, and 52
|
ACQ-6 is simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.
The 6-point self-administered scale has items measuring asthma symptoms and rescue inhaler use.
The ACQ score is the mean of the questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).
|
Day 1 (baseline), Weeks 16, 32, and 52
|
Change in absolute eosinophil counts (AEC)
Time Frame: Day 1 (baseline), Weeks 16, 32, and 52
|
Change from baseline, at Weeks 16, 32, and 52.
|
Day 1 (baseline), Weeks 16, 32, and 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sady Alpizar, MD, Clinical Research Trials of Florida, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 8, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
March 27, 2024
First Submitted That Met QC Criteria
April 24, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Leukocyte Disorders
- Eosinophilia
- Hypereosinophilic Syndrome
- Asthma
- Pulmonary Eosinophilia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Dopamine Agonists
- Dopamine Agents
- Antioxidants
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pramipexole
- Dexpramipexole
Other Study ID Numbers
- AR-DEX-22-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Asthma
-
Areteia TherapeuticsRecruitingAsthma Attack | Eosinophilic Asthma | Asthma; EosinophilicUnited States, United Kingdom, Romania, Poland
-
Lithuanian University of Health SciencesRecruitingAllergic Asthma | Severe Eosinophilic AsthmaLithuania
-
AstraZenecaCompletedSevere Eosinophilic AsthmaSpain
-
Medical University of GrazNot yet recruitingSevere Eosinophilic Asthma
-
AstraZenecaRecruiting
-
AstraZenecaActive, not recruitingSevere Eosinophilic AsthmaCanada
-
University of RostockUnknownImpact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic AsthmaSevere Eosinophilic AsthmaGermany
-
Medical University of LodzGlaxoSmithKlineNot yet recruitingAsthma; EosinophilicPoland
-
Sotiria General HospitalUnknownSevere Eosinophilic AsthmaGreece
-
Areteia TherapeuticsRecruitingAsthma | Eosinophilic Asthma | Asthma; EosinophilicUnited States, South Africa, United Kingdom, Korea, Republic of
Clinical Trials on Dexpramipexole Dihydrochloride
-
Areteia TherapeuticsRecruitingAsthma | Eosinophilic Asthma | Asthma; EosinophilicUnited States, South Africa, United Kingdom, Korea, Republic of
-
Areteia TherapeuticsRecruitingAsthma | Eosinophilic Asthma | Asthma; EosinophilicUnited States, United Kingdom, Georgia, Romania, Brazil, Bulgaria, Korea, Republic of, Poland, Serbia, Argentina
-
Areteia TherapeuticsRecruitingAsthma Attack | Eosinophilic Asthma | Asthma; EosinophilicUnited States, United Kingdom, Romania, Poland
-
Knopp BiosciencesCompletedAmyotrophic Lateral SclerosisUnited States
-
Daiichi Sankyo, Inc.No longer availableAcute Myeloid Leukemia With Gene Mutations
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Providence VA Medical CenterBioMarin Pharmaceutical; LifespanCompletedHeart Failure | Cardiovascular DiseaseUnited States
-
AllerdermCompleted
-
Knopp BiosciencesCompleted
-
Knopp BiosciencesCompleted